生产企业：Akari Therapeutics Plc
AKTX-101 is an investigational TROP2-targeting ADC with a PH1 RNA spliceosome-modulating payload, developed by Akari Therapeutics for KRAS-mutated pancreatic cancer. IND-enabling studies are underway with a Phase 1 trial expected by mid-2027.
AKTX-101 is an investigational TROP2-targeting ADC with a PH1 RNA spliceosome-modulating payload, developed by Akari Therapeutics for KRAS-mutated pancreatic cancer. IND-enabling studies are underway with a Phase 1 trial expected by mid-2027.
共 1 项相关疾病
